Foretinib has also shown antitumor activity in clinical studies of papillary renal cell carcinoma and hepatocellular carcinoma [24, 25], and may have the potential to prevent tumor growth in SCCHN, chiefly by reducing tumor cell proliferation and metastasis through HGF/MET inhibition and decreasing angiogenesis through VEGFR2 pathway inhibition. This evidence concerns the gene MET and neoplasm.